Live · 06 Oct 2026 SPX 7,773.95 +0.66% NDX 31,076.44 +0.87% VIX 15.52 +1.37% GOLD 4,169.00 +0.29% CL 88.37 -1.19% BTC 85,282.58 -0.59%
Titan Protect
Join the Desk
NAS100 31,076 +0.87% S&P 7,774 +0.66% GOLD $4,169 +0.29% BTC $85,283 −0.59% VIX 15.52 +1.37% live tape · as of 07:26 UTC
The Screen · Healthcare · Semiconductor Equipment & Materials

KPJ Healthcare

0166.KL · BURSA MALAYSIA · MYR · Market cap $8.2B · 6,000 employees

Inari Amertron Berhad engages in the provision of electronic manufacturing, outsourced semiconductor assembly, and testing services for radio frequency, fiber-optics transceivers, optoelectronics, memory modules, sensors…

FAIL · Does not pass the screen
2.64 MYR

Screen close, 2026-09-18 · not a live quote
Last reviewed 18 days ago

Screened 2026-09-18 · the tape above runs as of 07:26 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
1.321.351.55

What this means: price 2.64 against the desk's fair-value range, base estimate 1.35, over the last year.

Current read
Accumulation ?
AVOID · screened 2026-09-18
  • Trend Accumulation
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options no verdict drawn today, left as found
  • Ethical does not pass the values gate
Price2.64 MYR
Fair value1.35
Ethical score70.0/100
RatingAVOID
Our investment reviews on this name
2026-09-18Read Accumulation2.16+22.2% to today ✓
2026-07-02Read Markup2.16+22.2% to today ✓

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

Daily reads →Latest news →The method →Compare →
The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its accumulation label.

KPJ Healthcare holds its Accumulation at $2.64. Consolidating, no directional conviction, held for 47 days.

As held on the ledger · 2026-09-18
PhaseAccumulation
Quantitative stateConsolidating, no directional conviction, held for 47 days
Price at the screen$2.64
Valuation66.00 trailing · 37.52 forward price to earnings
Values screenFAIL · score 70.0
Beta0.81
The Workings

Five Screens, Shown in Full

Does not pass. Accounts receivable

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 0.43% Below 33% Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 0.00% Below 33% Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. Pass
Receivables 70.43% Below 49% Money owed to the company is 70.4% of assets, above the 49% limit. Fail
Revenue purity 5.01% Below 5% 5.0% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

KPJ Healthcare's business is fine, but its receivables are about 70% of its assets, well over the ~49% line, so it does not pass on the financial screens.

Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.

What the Numbers Say It Is Worth

The Fair Value Range

Our framework reads AVOID: it trades above our $1.35 fair value estimate.

1.32Conservative1.35Base case1.55Growth case 2.64Price

Fair value range in MYR, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. The price runs 49.0% above the base estimate.

The Street's Range
1.40Street low 2.10Street average 2.95Street high 2.64Price

Third-party analyst targets: 19 covering, consensus Hold. The average target sits −20% from the screen price.

Reading the gap · Both our model and the Street see limited upside at this price.

Price History & Projections
$3.5$2.3$1.1TODAY5y agoPROJECTIONStreet high$2.95 +31%Street avg$2.10 -7%Our fair value$1.35 -40%Conservative$1.32 -41%

Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it gives us pause

At 37.5x forward earnings, the price already runs ahead of the business. It trades 49% above our $1.35 fair value, so you would be buying at a premium, not a discount.

The fundamentals · plain-English read
Forward P/E37.5xexpensive: the price assumes strong growth ahead
Trailing P/E66.0xexpensive: the price assumes strong growth ahead
EPS, trailing0.04
EPS, forward0.07
Revenue growth-13.8%revenue is shrinking
Profit margin14.2%thin but positive margins
Return on equity5.4%a modest return on shareholder capital
Dividend yield185.00%
Debt to equity0.45minimal debt: a conservative balance sheet
Beta0.81steadier than the market
52-week range1.21 - 2.67
Market cap$8.2B
Employees6,000

The risks · The things to watch: its business and earnings are exposed to Malaysia and to currency swings.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

0166.KL trades on BURSA MALAYSIA (the company is based in Malaysia). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-10-02 Accumulation $2.64 +22.2% Entry 8

The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 22.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (19 analysts) rates it buy, with a mean price target of $2. Since the last review it its composite score eased.

2026-09-18 Accumulation · changed $2.16 +0.0% Entry 7

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (19 analysts) rates it buy, with a mean price target of $2.

2026-08-19 Markup $2.16 +0.0% Entry 6

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (19 analysts) rates it buy, with a mean price target of $2.

2026-07-19 Markup $2.16 +0.0% Entry 5

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (19 analysts) rates it buy, with a mean price target of $2.

2026-07-18 Markup $2.16 +0.0% Entry 4

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 14%. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (19 analysts) rates it buy, with a mean price target of $2.

2026-07-15 Markup $2.16 +0.0% Entry 3

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-03 Markup $2.16 +0.0% Entry 2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Markup $2.16 Entry 1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $1.91 +17.8% · $1,178 +17.8%
2 months $1.43 +57.3% · $1,573 +57.3%
3 months $1.29 +74.4% $0.01 $1,752 +75.2%
6 months $1.80 +24.8% $0.02 $1,261 +26.1%
1 year $1.98 +13.7% $0.04 $1,155 +15.5%
2 years $3.31 -32.1% $0.09 $707 -29.3%
3 years $2.30 -2.3% $0.19 $1,059 +5.9%
5 years $2.74 -17.8% $0.36 $954 -4.6%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever 0166.KL does next, these words stay.

KPJ Healthcare · 0166.KL · Accumulation · $2.64
Recorded 2026-09-18 · before the outcome · scored mechanically

All of today's entries → See the running score →
Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.